Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Enzalutamide (Primary) ; Everolimus (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 31 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 31 Jan 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2019.